Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$0.19.

  • Allogene Therapeutics' EPS (Basic) rose 4062.5% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.98, marking a year-over-year increase of 3717.95%. This contributed to the annual value of -$1.32 for FY2024, which is 3673.44% up from last year.
  • As of Q3 2025, Allogene Therapeutics' EPS (Basic) stood at -$0.19, which was up 4062.5% from -$0.23 recorded in Q2 2025.
  • Allogene Therapeutics' 5-year EPS (Basic) high stood at $0.01 for Q4 2021, and its period low was -$0.69 during Q1 2023.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.38 (2024), whereas its average is -$0.42.
  • In the last 5 years, Allogene Therapeutics' EPS (Basic) skyrocketed by 10092.59% in 2021 and then plummeted by 690000.0% in 2022.
  • Quarter analysis of 5 years shows Allogene Therapeutics' EPS (Basic) stood at $0.01 in 2021, then tumbled by 6900.0% to -$0.68 in 2022, then rose by 25.0% to -$0.51 in 2023, then skyrocketed by 42.08% to -$0.3 in 2024, then surged by 35.68% to -$0.19 in 2025.
  • Its EPS (Basic) stands at -$0.19 for Q3 2025, versus -$0.23 for Q2 2025 and -$0.28 for Q1 2025.